[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590846":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":34,"overallOfficials":13,"centralContacts":48,"locations":54,"responsibleParty":68,"collaborators":13,"id":70,"slug":13,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":13,"enrollmentInfo":79,"targetDuration":13,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":57,"whyStopped":13,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Boryung Pharmaceutical Co., Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"HbA1c (%) change at 24 weeks compared to the baseline (Visit 2)","The mean change of HbA1c at 24 weeks compared to the baseline (Visit 2) is evaluated.","From baseline to end of treatment at 24 weeks",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21,28],{"label":22,"type":23,"description":24,"interventionNames":25},"Metformin + Dapagliflozin 10mg\u002FPioglitazone 30mg","EXPERIMENTAL","One tablet of Metformin and one tablet of Dapagliflozin 10mg\u002FPioglitazone 30mg administered orally once daily for 24 weeks.",[26,27],"Drug: Metformin","Drug: Dapagliflozin\u002FPioglitazone",{"label":29,"type":30,"description":31,"interventionNames":32},"Metformin + Dapagliflozin 10mg\u002FSitagliptin 100mg","ACTIVE_COMPARATOR","One tablet of Metformin and one tablet of Dapagliflozin 10mg\u002FSitagliptin 100mg administered orally once daily for 24 weeks.",[26,33],"Drug: Dapagliflozin\u002FSitagliptin",[35,40,44],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":13},"DRUG","Metformin","The dosage and dose frequency are maintained as they were before the screening.",[22,29],{"type":36,"name":41,"description":42,"armGroupLabels":43,"otherNames":13},"Dapagliflozin\u002FPioglitazone","Dapagliflozin 10mg\u002FPioglitazone 30mg QD",[22],{"type":36,"name":45,"description":46,"armGroupLabels":47,"otherNames":13},"Dapagliflozin\u002FSitagliptin","Dapagliflozin 10mg\u002FSitagliptin 100mg QD",[29],[49],{"name":50,"role":51,"phone":52,"phoneExt":13,"email":53},"Oh","CONTACT","+82 2-708-8000","syoh@boryung.co.kr",[55],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":13,"cosmosGeoPoint":62,"geoPoint":67,"contacts":13},"The Catholic University of Korea, Seoul St. Mary's Hospital","RECRUITING","Seoul","Seocho District","06591","South Korea",{"type":63,"coordinates":64},"Point",[65,66],126.9784,37.566,{"lat":66,"lon":65},{"type":69,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100590846",false,"NCT06972732","A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes","A Randomized, Open-label, Active-controlled, Parallel, Multicenter, Phase IV Clinical Trial to Compare the Efficacy and Safety of Switching Metformin+SGLT2-i+Dipeptidyl Peptidase-4-inhibitor(DPP-4-i) to Metformin+SGLT2-i+TZD in Patients With Type 2 Diabetes","TELOS","Inclusion Criteria:\n\n* Has voluntarily agreed to participate in this clinical trial.\n* Adults over 19 years of age\n* Diagnosed with type 2 diabetes\n\nExclusion Criteria:\n\n* Has severe renal and liver disorders\n* Has type 1 diabetes\n* Those who are participating or have participated in other clinical trials and administered their investigational products within 8 weeks before the screening date for this study\n* Those who are deemed ineligible to participate in the study by the investigator","ALL","19 Years",{"count":80,"type":81},204,"ESTIMATED","INTERVENTIONAL",[84],"PHASE4","This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.",[87],"Type 2 Diabetes",[89],"type 2 diabetes","2025-09-11",{"date":92,"type":93},"2025-09-15","ACTUAL",{"date":95,"type":93},"2025-06-11",{"date":97,"type":81},"2026-10-01",{"name":5,"class":6},1]